If you have been reading about somatotroph and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-19. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
=== Pharmacodynamics === Luvesilocin is a prodrug that is metabolized into 4-HO-DiPT. This metabolite is an analogue of the neurotransmitter serotonin and acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor. Activation of the serotonin 5-HT2A receptor is thought to be specifically responsible for the hallucinogenic effects of serotonergic psychedelics. 4-HO-DiPT produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. In drug discrimination tests, 4-HO-DiPT fully substituted for the psychedelic drug DOM, with 5-fold lower potency than DOM and 2-fold lower potency than psilocin (4-HO-DMT). The drug activates basolateral amygdala (BLA) interneurons via the serotonin 5-HT2A receptor to enhance GABAergic inhibition of principal neurons in the BLA, which may mediate an anxiolytic effect of suppression of learned fear (fear extinction) in rodents.
=== Iron chelation === Multiple blood transfusions lead to severe iron overload, as the body eventually breaks down the hemoglobin in donated cells. This releases iron which it is unable to excrete. Iron overload may be treated by chelation therapy with the medications deferoxamine, deferiprone, or deferasirox. Deferoxamine is only effective as a daily injection, complicating its long-term use. Adverse effects include primary skin reactions around the injection site and hearing loss. Deferasirox and deferiprone are both oral medications, whose common side effects include nausea, vomiting and diarrhea.
=== First reaction: entering the urea cycle === Before the urea cycle begins ammonia is converted to carbamoyl phosphate. The reaction is catalyzed by carbamoyl phosphate synthetase I and requires the use of two ATP molecules. The carbamoyl phosphate then enters the urea cycle.
Sources: en.wikipedia.org
Myrophine (Myristylbenzylmorphine) is an opiate analogue that was developed in 1952. It is a derivative of morphine. Myrophine is substituted with a 3-benzyl group and a 6-myristyl chain. It is metabolised to form benzylmorphine and then further to morphine, and so is a long-acting prodrug for morphine, but with a slow onset of effects. It is weaker than morphine as an analgesic but longer-lasting in effects, and was thought to have more local anesthetic effect than morphine, though with a somewhat greater tendency to cause reactions like itching and rash. In addiction studies conducted in human subjects in the 1950s, myrophine did not substitute for morphine in withdrawal, did not produce notable morphine-like effects, and did not produce addiction or dependence regardless of dose or how it was administered. Consequently, it was thought to be useful in treating pain in addicts who were being detoxified from other opioid drugs. It is a Schedule I drug in the US, considered to have high potential for abuse and no medical applications, and is controlled under international drug conventions. Myrophine is almost invariably used as the hydrochloride (free base conversion ratio 0.94) and has a DEA Administrative Controlled Substance Control Number of 9308. Myrophine is a Class A controlled substance in the UK, and is on the UN's Yellow list.
Radium has 33 known isotopes with mass numbers from 202 to 234, all of which are radioactive. Four of these – 223Ra (half-life 11.4 days), 224Ra (3.64 days), 226Ra (1600 years), and 228Ra (5.75 years) – occur naturally in the decay chains of primordial thorium-232, uranium-235, and uranium-238 (223Ra from uranium-235, 226Ra from uranium-238, and the other two from thorium-232). These isotopes nevertheless still have half-lives too short to be primordial radionuclides, and only exist in nature from these decay chains. Together with the mostly artificial 225Ra (15 d), which occurs in nature only as a decay product of minute traces of neptunium-237, these are the five most stable isotopes of radium. All other 27 known radium isotopes have half-lives under two hours, and the majority have half-lives under a minute. Of these, 221Ra (half-life 28 s) also occurs as a 237Np daughter, and 220Ra and 222Ra would be produced by the still-unobserved double beta decay of natural radon isotopes. At least 12 nuclear isomers have been reported, the most stable of which is radium-205m with a half-life between 130~230 milliseconds; this is still shorter than twenty-four ground-state radium isotopes. 226Ra is the most stable isotope of radium and is the last isotope in the (4n + 2) decay chain of uranium-238 with a half-life of over a millennium; it makes up almost all of natural radium. Its immediate decay product is the dense radioactive noble gas radon (specifically the isotope 222Rn), which is responsible for much of the danger of environmental radium.
== Cancer == Hsp70 is overexpressed in melanoma and underexpressed in renal cell cancer. In breast cancer cell line (MCF7) has been found that not only Hsp90 interacted with estrogen receptor alpha (ERα) but also Hsp70-1 and Hsc70 interacted with ERα too. Given the role of heat shock proteins as an ancient defense system for stabilizing cells and eliminating old and damaged cells, this system has been co-opted by cancer cells to promote their growth. Increased Hsp70 in particular has been shown to inhibit apoptosis of cancer cells, and increased Hsp70 has been shown to be associated with or directly induce endometrial, lung, colon, prostate, and breast cancer, as well as leukemia. Hsp70 in cancer cells may be responsible for tumorigenesis and tumor progression by providing resistance to chemotherapy. Inhibition of Hsp70 has been shown to reduce the size of tumors and can cause their complete regression. Hsp70/Hsp90 is a particularly attractive target for therapeutics, because it is regulated by the inhibition of its ATPase activity, while other HSPs are regulated by nucleotides. Several inhibitors have been designed for Hsp70 that are currently in clinical trials, though as of now HSP90 inhibitors have been more successful. In addition, Hsp70 has been shown to be a regulator of the immune system, activating the immune system as an antigen. Thus, tumor-derived Hsp70 has been suggested as a potential vaccine or avenue to target for immunotherapy.
Sources: en.wikipedia.org
=== Alzheimer's === Neurodegenerative diseases occur from loss of neuronal structure and function. This progressive degeneration of neurons is irreversible. Alzheimer's is a neurodegenerative disease that begins with short-term memory loss progressing to loss of control over heartbeat and breathing. It has been over 100 years since Alois Alzheimer first presented the world disease to the world in 1906. There is evidence for the efficacy of intranasal delivery to treat Alzheimer's. Intranasal delivery of insulin showed greater memory improvement in patients with Alzheimer's than in healthy individuals. Increased microglial activation inflammation are characteristics of Alzheimer's. Animal studies show intranasal administration of pro-resolving lipid mediators decreased both factors, slowing pathogenesis of this disease. Delivering a novel peptide via intranasal route reduced amyloid beta plaques, a defining trait of Alzheimer's and enhanced cognitive functions. Intranasal delivery of anti-Alzheimer's drug dispersed through hydrogel in rabbits demonstrated higher bioavailability compared to oral tablets. MiR132 is an RNA molecule that regulates neuronal morphology and maintains survival. This molecule is downregulated with Alzheimer's. A study administered PEG-PLA nanoparticles loaded with this miRNA to mice through the nasal route. This novel therapy showed increased expression of miR132 and improved memory function.
== Research and Discoveries == Strahl is a pioneer in the field of epigenetics, with contributions to the study of Chromatin biology. As a postdoctoral fellow in C. David Allis’ laboratory, helped to establish the identity of the first lysine and arginine histone methyltransferases and how they contribute to transcriptional activation and heterochromatin formation. Some examples include the discovery of the first histone methyltransferases that target lysine 4 (Set1), lysine 9 (SUV39H1), and lysine 36 of histone H3 (Set2/SETD2) and arginine 3 of histone H4 (PRMT1). Strahl also helped to develop the first antibodies for methylated histones in the Allis laboratory. In 2000, Strahl and Allis put forward the idea of the “histone code hypothesis”, which aimed to explain how multiple histone modifications function together to control chromatin structure and function. The early years of the Strahl laboratory, research focused on the roles of histone methylation and histone ubiquitylation in gene transcription. He linked histone H2B ubiquitylation to the regulation of H3 lysine 79 methylation and in transcriptional elongation and determined how H3 lysine 36 methylation is coupled to RNA Polymerase II and repressive chromatin during transcription elongation. His group also defined the key roles of several histone chaperones (e.g., Spt6) that function in transcription In more recent years, Strahl turned his attention to how chromatin-associated proteins engage histones and their modifications.
Gillnets may be used in fish maw fishing. However, gillnets can have high rates of bycatch. In the Gulf of California, gillnets set by poachers to catch totoaba also inadvertently catch vaquita, a critically endangered porpoise. The population of vaquita dropped 92% from 1997 to 2015, in large part from totoaba poaching. The 2019 documentary Sea of Shadows documented and condemned totoaba poaching and its negative effect on the vaquita population. In the Kikori River Delta of Papua New Guinea, gillnet fishermen trying to target the scaly croaker Nibea squamosa regularly trap elasmobranchs and dolphins as bycatch: targeted fish make up less than a quarter of the total catch.
==== Temgicoluril ==== Temgicoluril (Mebicar) is an anxiolytic produced in Latvia and used in Eastern Europe. Temgicoluril has an effect on the structure of limbic-reticular activity, particularly on the hypothalamus, as well as on all four basic neuromediator systems – γ aminobutyric acid (GABA), choline, serotonin and adrenergic activity. Temgicoluril decreases noradrenaline, increases serotonin, and exerts no effect on dopamine.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.